Infectious Disease Mouse Models (HIV, HBV)
Infectious disease mouse models for studying HIV, HBV and other infectious diseases are available from TransCure bioServices.
The CD34+ Humanized Mice, a promising player in the preclinical HIV research arena
CD34+ Humanized Mice have already demonstrated their value in HIV research. They have been used to model key aspects of HIV infection, including viral replication, CD4+ T cell depletion, immune response, and latency. They’ve also been instrumental in testing the efficacy of antiretroviral drugs and potential HIV vaccines.
Make sure to check out our complimentary webinar “How Humanized Mice Studies Can Accelerate Preclinical Research in Infectious Diseases“, a 2 minute introduction is provided here.
The following case studies illustrate the significant contributions of TransCure bioServices Humanized mice in advancing HIV preclinical research. Using CD34+ humanized mice, researchers are now able to accelerate the development and testing of potential therapeutics, emphasizing the importance of these models in the fight against HIV.
Case Study #1: The Development of a long-acting antiviral agent
Case Study #2: GS-CA1, A New Small-Molecule HIV Capsid Inhibitor
Case Study #3: Targeting the HIV reservoir using Venetoclax as a BCL-2 inhibitor
Wensel D, Sun Y, Davis J, Li Z, Zhang S, McDonagh T, Langley D, Mitchell T, Tabruyn S, Nef P, Cockett M, Krystal M. GSK3732394: a Multi-specific Inhibitor of HIV Entry. J Virol. 2019 Sep 30;93(20):e00907-19. doi: 10.1128/JVI.00907-19. PMID: 31375580; PMCID: PMC6798092.
Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, Stepan GJ, Jin D, Wong MH, Perreira JM, Singer E, Papalia GA, Hu EY, Zheng J, Lu B, Schroeder SD, Chou K, Ahmadyar S, Liclican A, Yu H, Novikov N, Paoli E, Gonik D, Ram RR, Hung M, McDougall WM, Brass AL, Sundquist WI, Cihlar T, Link JO. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat Med. 2019 Sep;25(9):1377-1384. doi: 10.1038/s41591-019-0560-x. Epub 2019 Sep 9. PMID: 31501601; PMCID: PMC7396128.
Chandrasekar AP, Cummins NW, Natesampillai S, Misra A, Alto A, Laird G, Badley AD. The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model. J Virol. 2022 Dec 21;96(24):e0173022. doi: 10.1128/jvi.01730-22. Epub 2022 Nov 30. PMID: 36448802; PMCID: PMC9769373.